In prespecified subgroup analyses, SGLT2 inhibitor use was associated with a reduced risk of all-cause mortality, regardless of age, cardiovascular disease status, eGFR category, albuminuria status, BMI category, and baseline use of insulin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics (Figure 2; eTable 3 in the Supplement). Here, SLC5A2 is linked to cardiovascular disorder.